Medical News
The work was carried out on behalf of the Early Cancer Detection
Consortium, a group of nearly 40 organisations, including universities,
hospitals and commercial companies.
The next step will be to look in detail at the research behind each
biomarker, to check that it is robust and that the biomarker could
feasibly be used as part of a screening test. Biomarkers will also be
grouped by cancer type at this stage. The validated biomarkers will then
be put through a clinical study, using samples from cancer patients and
healthy controls, to check how effectively they identify the presence
of cancer.
Article: Building the Evidence Base of Blood-Based Biomarkers for Early Detection of Cancer: A Rapid Systematic Mapping Review, Lesley Uttley, Becky L. Whiteman, Helen Buckley Woods, Susan Harnan, Sian Taylor Philips, Ian A. Cree,
EBioMedicine, doi: 10.1016/j.ebiom.2016.07.004, published online 6 July 2016.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.